Extrait

The primary objective of the study is to assess the antitumor activity, as measured by the pathologic complete response (pCR) rate in the breast, of neoadjuvant treatment with two different sequential treatment regimens (AP->Doc, AC->Doc) in female patients with early breast cancer (T2-T4/N0-N2/M0).

Critère d'inclusion

• Females with histologically confirmed diagnosis of primary early breast cancer, with a tumor size ≥ 2 cm, of Stages T2-T4/N0-2/, as confirmed by incisional or core biopsy M0 will be treated with chemotherapy prior to surgery

Liens

• ictrp
• euctr
• ictrp
• ictrp
• euctr
• euctr